Page 1

Report: Therapeutic Class Report Overview - Future Of GPR Agonist Category: Healthcare

Insert Image Height - 3.60 Width – 4.98

www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview - Future Of GPR Agonist Report Details

• • • • • • •

Publish date: 4th Feb, 2013 Number of slides: 20 Geographic coverage: Global Available format: PDF, CD, Hardcopy Price for Single User License: USD 1,000 Delivery Time: Within 1 business day Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google Wallet, PayPal

www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview - Future Of GPR Agonist Report Insights

• Despite the innovation and introduction of distinct targets in the market for the oral treatment of Type 2 diabetes, 60% of diabetics still exhibit progressive worsening of glycemic control • This results in most of the patients ending up taking insulin daily • Increasing epidemiology of type 2 diabetes due to genetic or lifestyle changes, as well as micro or macro-vascular complication associated with diabetes, seeks newer options for treating diabetes which can address other consequences along with HbA1c reduction • Selective PPAR agonists, DGAT1 (diglyceride Acyltransferase 1) inhibitors, GPR (G-protein receptor) agonist, Glucokinase inhibitors are some of the early targets which are in clinical development www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview - Future Of GPR Agonist Report Insights (Continued)

• Such targets have the potential to come into the clinic in the next decade • Amongst these novel targets, a few candidates from GPR (G-protein couple receptors) agonist are nearing late stage development • Ability to directly modulate insulin and GLP-1 secretion in glucose depended manner is the key trait of this class • Through this, GPR agonist controls hyperglycemia and provides weight loss advantage • Recent publications suggest GPR agonist have complementary action with DPP-IV inhibitors

www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview - Future Of GPR Agonist Report Coverage

• Merits and demerits of developing GPR agonist • Pipeline GPR agonist together with sales estimate of key pipeline candidate through 2020 across the world

www.researchonglobalmarkets.com


Report: Therapeutic Class Report Overview - Future Of GPR Agonist Table of Contents

• Investment Drivers • Unmet need exists for an oral option for Treatment of Type 2 diabetes • Key attributes of Major Anti-diabetic drugs • Oral Islets GPCR agonist - Direct action on Insulin secretion and GLP-1 secretion • Key advantage/ Risk of developing GPR agonist • Difference exists amongst GPCR family • GPR 40 agonist vs. GPR 119 agonist • Pipeline GPR agonist • Annexure- I and annexure- II www.researchonglobalmarkets.com


Interested in this report? To view more details regarding this premium market research report, Please click here

For further information, get in touch with us: E-mail: support@researchonglobalmarkets.com Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600 About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports Industry Segments Automotive & Transport

Consumer goods

Agriculture

Food and Beverage

Energy and Utilities

Public Sector

Manufacturing & Construction

Healthcare

Media & Entertainment

IT, Telecom & Electronics

Services

Others

www.researchonglobalmarkets.com

Future Of GPR Agonist | Therapeutic Class Report Overview | Market Research Report  

Market Research Report Abstract : This report discuss in details about the merits/demerits of developing GPR agonist, pipeline GPR agonist...

Read more
Read more
Similar to
Popular now
Just for you